Skip to main content
. 2022 Feb 4;6(3):1015–1024. doi: 10.1182/bloodadvances.2021006106

Table 4.

Proposed prognostic score for PFS for patients with WM treated with ibrutinib monotherapy

Variables HR (95% CI) P
CXCR4 mutations 2.51 (1.28-4.89) .001
 Platelet count <100 K/ul 1.98 (1.17-3.36) .07
Stratum Score n (%) Failed 5-y PFS rate, % (95% CI) HR (95% CI)
 Low 0 144 (60) 28 72 (60-82) 1.0 (Ref)
 Intermediate 1 76 (32) 25 44 (27-60) 2.2 (1.3-3.8)
 High 2 21 (9) 9 20 (1-55) 4.7 (2.2-10.1)